Shoulder Innovations went public late last month, with the firm pricing the debut at $15 per share. The stock has slipped about 16% in August.
Get this delivered to your inbox, and more info about our products and services.
Jay Woods breaks down the charts in Steris.
BofA analysts are bullish on this German medtech name ahead of its full-year earnings report.
Chart analyst Frank Cappelleri goes through the charts that make this stock an attractive play.
Shares have pulled back more than 36% so far in 2025.
Chart analyst Frank Cappelleri breaks down the technical outlook on the biotech stock.
Goldman Sachs sees shares of Biohaven rallying 114% after plunging 72% over the past 12 months.
